BRIEF-Beigene Receives FDA Breakthrough Therapy Designation For Zanubrutinib In Mantle Cell Lymphoma

Jan 14 (Reuters) - Beigene Ltd:

* BEIGENE RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZANUBRUTINIB IN MANTLE CELL LYMPHOMA Source text for Eikon: Further company coverage: